Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.43 |
| ▸ | PAK1 | Q13153 | 8/20 | 0.42 |
| ▸ | SUV39H1 | O43463 | 1/20 | 0.40 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.40 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.40 |
| ▸ | STK4 | Q13043 | 1/20 | 0.39 |
| ▸ | STK3 | Q13188 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 5/20 | 0.39 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 3/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | AKT2 | P31751 | 1/20 | 0.38 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4583403 | 0.91 | CYP1A2 (0.52) | CYP1A2CYP2D6PDGFRBPAK1SUV39H1 | |
| SCHEMBL4582469 | 0.87 | ALDH1A1 (0.52) | PDGFRB | |
| SCHEMBL4582848 | 0.85 | CYP1A2 (0.49) | CYP1A2CYP2D6PDGFRBPAK1SUV39H1 | |
| SCHEMBL4582930 | 0.85 | CYP1A2 (0.53) | CYP1A2CYP2D6PDGFRBPAK1SUV39H1 | |
| SCHEMBL4017800 | 0.83 | PAK1 (0.55) | CYP1A2CYP2D6PDGFRBPAK1SUV39H1 | |
| SCHEMBL4582252 | 0.81 | PDGFRB (0.47) | PDGFRB | |
| SCHEMBL4583933 | 0.79 | CNR1 (0.49) | CYP1A2CYP2D6PDGFRBPAK1SUV39H1 | |
| SCHEMBL4583794 | 0.79 | CNR1 (0.49) | CYP1A2CYP2D6PDGFRBPAK1SUV39H1 | |
| SCHEMBL4582250 | 0.78 | HRH4 (0.42) | PAK1MALT1 | |
| SCHEMBL4583140 | 0.78 | ALDH1A1 (0.56) | PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080125435-A1 | 1-(Het)aryl-3-[hetaryl-piperidin-4-yl]-thioureas as modulators of the EP2 receptor | BAYER SCHERING PHARMA AG (DE) | 2008-05-29 | — | — | US | claimed |
| EP-1903037-A1 | 1-(hetero)aryl-3-[heteroaryl-piperidin-4yl]-thiourea derivatives as modulators of EP2 receptors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-03-26 | — | — | EP | claimed |
| US-20080125435-A1 | 1-(Het)aryl-3-[hetaryl-piperidin-4-yl]-thioureas as modulators of the EP2 receptor | BAYER SCHERING PHARMA AG (DE) | 2008-05-29 | — | — | US | disclosed |
| EP-1903037-A1 | 1-(hetero)aryl-3-[heteroaryl-piperidin-4yl]-thiourea derivatives as modulators of EP2 receptors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125435-A1 | 1-(Het)aryl-3-[hetaryl-piperidin-4-yl]-thioureas as modulators of the EP2 receptor | PTGER2, PTGER1, PTGES2 | CYP1A2 88/4885CYP2D6 247/4885PDGFRB 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.